Chinanews, May 8th, "Brazil towns defeated the new crown pneumonia through a unique experiment." On May 7, an article in the US "Wall Street Journal" attracted attention.
The picture shows a screenshot of the US "Wall Street Journal" report.
The report mentioned was Serrana, a small town with about 45,000 inhabitants in southeastern Brazil.
In the past few months, an experiment has been going on here-to promote more people to be vaccinated with the China Coxing vaccine.
Now, the results of the experiment are gradually becoming clear: Although the epidemic is still raging in many places in Brazil, Serrana's life has begun to "return to normal."
According to reports, like many places in Brazil, Serana was originally a town with a higher rate of new crown infections in the state of Sao Paulo, Brazil.
Until February, in order to study the effect of the vaccine and the follow-up situation of the Brazilian epidemic, the Brazilian Butantan Institute launched the "Plan S" to vaccinate all local people over the age of 18 with the Chinese Kexing vaccine.
At that time, Brazil’s National Health Inspection Agency had announced that it would grant China Kexing vaccine emergency use license and promote vaccination.
According to an interview conducted by the British Broadcasting Corporation (BBC) on February 19, many local people lined up at the vaccination site early.
A local resident said that she even arrived at the vaccination site at 8 o'clock just to get to the front of the line.
According to the British Broadcasting Corporation (BBC), in the week after the "Plan S" was launched, a local resident said that she even arrived at the vaccination site at 8 o'clock and waited in line.
Image source: BBC News video screenshot.
Ferreira, a 57-year-old local painter, felt that being able to be vaccinated was a "gift" after experiencing the death of six friends from the epidemic.
He said: "The vaccine currently in use is Kexing Vaccine. We trust it and are happy to get it."
In April, the Butantan Institute announced the completion of the "Plan S", saying that 27,150 people in the area have been vaccinated with two doses, reaching about 97.7% of the target population.
Initial results showed that under the dual effects of multi-person vaccination and strict epidemic prevention in the state, the number of confirmed cases in Serrana in a single month has been greatly reduced, and the long queue of patients waiting in the hospital for the use of ventilators has gradually disappeared.
Other researchers said that although it is too early to draw conclusions, the early results seem to be "exciting."
Today, in Serrana, children screaming and laughing across the main square, groups of friends stop to chat and sunbathe in the afternoon, the Wall Street Journal reported.
Omero, a 68-year-old retired architect, no longer keeps himself at home.
He took his wife and their one-year-old grandson for a walk, "We feel very free."
On January 17, 2021, local time, in Sao Paulo, Brazil, Brazil's first batch of new crown vaccination patients received the Chinese vaccine on the same day. Monica Karazhan, a 54-year-old nurse from the State of Sao Paulo, became the first Brazilian to receive the Coxing vaccine.
Undoubtedly, Serrana’s unique experience in fighting the epidemic “brings hope to countries in the world that are fighting the new crown epidemic”.
On May 7, the World Health Organization announced that the new crown vaccine of China National Pharmaceutical Group will be included in the emergency use list.
The new crown vaccine produced by China Kexing Company has also entered the final stage of emergency use authorization evaluation. The Associated Press reported that the WHO said it may make a decision next week.
Independent experts from the WHO Strategic Advisory Expert Group (SAGE) evaluated the Phase III clinical trials of Kexing Vaccine in China, Brazil, Indonesia, Turkey and Chile.
Experts say that Kexing vaccine has been authorized in 32 countries and regions, and about 260 million doses of vaccine have been distributed.
SAGE stated in an assessment report published on the WHO website: "We are very confident that two doses of Koxing vaccine are effective for adults (18-59 years old) to prevent new coronary pneumonia."